Sano Genetics, a Cambridge, UK-based provider of a software platform for precision medicine clinical trials, raised $11.4M in funding.
The round, which brought the total amount to $22M, was led by Plural.
The company intends to use the funds to further automate its processes.
Founded by Patrick Short (CEO), Charlotte Guzzo (COO) and William Jones (CTO), Sano Genetics is developing software to enable precision medicine. It combines genetic testing, recruitment, and long-term engagement in one platform, accelerating enrollment and simplifying operations for precision medicine teams and patients. The solution connects patients across four countries, including the UK, US, Australia and Canada, with pharmaceutical companies and biotech companies conducting clinical trials, making it easier for patients to access precision medical treatment and for companies to bring new, effective drugs to market quickly. The company works with pharmaceutical companies and biotechs to find, screen, and engage participants faster and more cost effectively, with researchers to increase efficiency and impact, and with patient advocacy groups to drive research with and for their communities.
Commenting on the news, Patrick Short said: “Precision medicine is transforming how we think about and approach healthcare, and clinical trials are the bedrock of precision drug development. In the past 12 months, we’ve scaled up our capacity to hold three times more trials than the year before and launched our first programme supporting families affected by ALS. I’m so pleased with everything the team has achieved so far and this new funding will help us to integrate LLMs and other AI tools to drive more productivity. This will help us continue our growth trajectory, particularly with the help of visionary investors like Carina Namih, who supported our seed round and is now supporting us again at Plural.“
FinSMEs
22/01/2024